Context: Tacrolimus (TAC), a calcineurin inhibitor, is commonly used as an immunosuppressive agent in organ transplantation, but its clinical use may be limited due to cardiotoxicity. Olmesartan (OLM; angiotensin receptor blocker) and aliskiren (ALK; renin inhibitor) may attenuate cardiotoxicity induced by TAC by inhibition of renin-angiotensin aldosterone system.
Objective: The aim of this study was to evaluate the effect of OLM and ALK on TAC-induced cardiotoxicity.
Materials And Methods: Male Wistar albino rats weighing 200-250 g (10-12 weeks old) were used in this study. Animals were divided into four groups. Group 1 received normal saline, group 2 received TAC (2 mg/kg, intraperitoneally for 14 d), group 3 received OLM (2 mg/kg, p.o. for 28 d) + TAC and group 4 received ALK (50 mg/kg, p.o. for 28 d) + TAC. TAC-induced cardiotoxicity was assessed biochemically and histopathologically.
Results: Treatment with OLM or ALK decreased the TAC-induced changes in biochemical markers of cardiotoxicity such as serum aspartate transaminase, creatine kinase and lactate dehydrogenase. OLM or ALK also attenuated the effects of TAC on oxidant-antioxidant parameters such as malondialdehyde, reduced glutathione and catalase. Histopathological and ultrastructural studies showed that OLM or ALK also attenuated TAC-induced cardiotoxicity.
Discussion And Conclusion: These results suggest that OLM as well as ALK has protective effects against TAC-induced cardiotoxicity; implying that angiotensin receptor blocker or renin inhibitor, respectively, may counteract cardiotoxicity associated with immunosuppressant use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/15376516.2014.963773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?
Allergol Select
March 2024
Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University and Ghent, University Hospital, Ghent, Belgium.
Article Synopsis
- Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition often treated with the anti-IL-5 antibody mepolizumab, which was approved as an additional therapy in 2021 when other treatments fail.
- Current guidelines for using mepolizumab in CRSwNP lack detailed instructions on monitoring, documentation, and discontinuation protocols.
- A literature review led to recommendations for following up on treatment, ensuring adherence to therapy schedules, and guidance on possible therapy interruptions or discontinuation for patients under the German healthcare system.
[Not Available].
Laryngorhinootologie
February 2023
Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Gent, Belgien.
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and sinuses. Eosinophilic inflammation is described as a common endotype. The anti-IL5 antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps when systemic glucocorticosteroids or surgery do not provide adequate disease control.
View Article and Find Full Text PDF[Not Available].
Laryngorhinootologie
November 2022
Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Gent, Belgien.
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the nasal and paranasal mucosa. A Type-2 inflammation is described as the most common endotype. Since October 2019 the anti-IL-4/-IL-13 antibody dupilumab has been approved in Germany as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps, when systemic corticosteroids alone or surgery do not provide adequate disease control.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!